Pre-made Plozalizumab benchmark antibody ( Whole mAb, anti-CCR2 therapeutic antibody, Anti-CKR2/CD192/CKR2A/CKR2B/CMKBR2/MCP-1-R/CC-CKR-2 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-447
Pre-Made Plozalizumab biosimilar, Whole mAb, Anti-CCR2 Antibody: Anti-CKR2/CD192/CKR2A/CKR2B/CMKBR2/MCP-1-R/CC-CKR-2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Plozalizumab (INN; hu1D9) is a humanized monoclonal antibody designed for the treatment of diabetic nephropathy and arteriovenous graft patency.
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
|Catalog No.||Package||List Price(In USD)||Discount off||Discount Price|
Size： 1mg | 10mg | 100mg
|Products Name (INN Index)||Pre-Made Plozalizumab biosimilar, Whole mAb, Anti-CCR2 Antibody: Anti-CKR2/CD192/CKR2A/CKR2B/CMKBR2/MCP-1-R/CC-CKR-2 therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||Millennium;Millennium Pharmaceuticals;Takeda;Takeda Oncology|
|Conditions Active||Atherosclerosis;Diabetic nephropathies;Malignant melanoma|
|Conditions Discontinued||Multiple sclerosis;Rheumatoid arthritis;Scleroderma;Solid tumours|
|Development Tech||Humanization by CDR Grafting|